Background: One to two percent of the population globally suffers from vitiligo, an acquired depigmentation condition of multifactorial etiology. Macules and patches of depigmentation characterize vitiligo. People's moods are affected greatly and depressingly by it. As a result, prompt and effective therapy is necessary. Many individuals are able to slow the advancement of the disease, acquire repigmentation, and achieve cosmetically appealing results with proper therapy. There is a wide range of treatments for vitiligo, including topical corticosteroids (TCS) as monotherapy (as for vitiligo local therapy) or in conjunction with phototherapy or other topical medications in generalized vitiligo. Intermittent administration of large (pharmacological) dosages to maximize therapeutic benefit and prevent side effects is known as dexamethasone oral mini pulse (OMP) treatment. Objective: to determine the success of oral dexamethasone in vitiligo management. Conclusion: In vitiligo patients, when corticosteroids are provided at the onset or at early stages of disease, they can reduce disease progression and promote repigmentation and in some cases total repigmentation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.